🇺🇸 ClinicalTrials.govClinicalTrials.gov · 试验状态变更Doubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·源无时间·以抓取为准·⟳ 抓取 20:13:34·⚡ 决策 10-21 20:16:42 +3m08s·6.3 天前
ClinicalTrials.gov 更新赛诺菲 SAR441566（balinatunfib）口服 TNFα 抑制剂中重度溃疡性结肠炎 II 期 SPECIFI-UC 试验记录，仅为常规注册表状态变更、无任何疗效数据
这是临床试验注册库的常规记录更新：研究数月前已在招募，正文只有方案设计、无疗效/安全性数据、无注册申报或合作等阶段迁移，对赛诺菲这一超大市值药企不构成任何可交易的基本面预期差；近期同类 UC 早期数据事件对 mega-cap 药企本身均无定价影响，本条强度更低。
📄 原文ClinicalTrials.gov · 试验状态变更↗ 原文
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to eval…
不做 Sanofi（赛诺菲）（SAN.FR）
NO_INCREMENTAL_FACT：ClinicalTrials.gov 对 NCT06867094（SAR441566/balinatunfib 治 UC 的 II 期 SPECIFI-UC）仅为常规注册表记录更新，研究 2026 年中已在招募，正文无疗效数据、无监管/合作/金额增量；对千亿欧元级市值的赛诺菲无可定价预期差，无做多 edge，也无任何利空可做空，美国 ADR（SNY.US）同理不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
NCT06867094（SAR441566/balinatunfib 口服 TNFα 抑制剂治 UC 的 II 期 SPECIFI-UC）仅发生 ClinicalTrials.gov 注册表例行更新，无数据读出、无新阶段、无金额，赛诺菲（SAN.PA/SNY.US）作为超大市值药企无可交易 edge，多空均不做。
消息传播链
- NCT06867094 记录发生状态变更并被抓取；展示内容为 SPECIFI-UC II 期试验设计（剂量探索、12周诱导+40周维持），无任何疗效数据或公司新闻稿配套，属注册库例行更新，无媒体扩散
关键理由
- 无做多逻辑：注册库方案文本更新不含疗效信号，且研究 2026 年中起即在招募，属公开存量信息，无预期差
- 无做空逻辑：本条无失败、无安全性事件、无下修，早期试验例行推进不构成任何净利空
主要风险
- 若本次状态变更实际附带了档案正文未展示的数据结果字段（如 Results first posted），结论需重判，但现有证据不支持该假设
- 赛诺菲后续若在学术会议公布 SPECIFI-UC 诱导期阳性/阴性顶线数据，将构成独立的新催化，需另行研判
反向证据
先例如何影响了这次决策
对本次决策的影响:确认不给任何方向的交易腿；不做 event_study 喂入，因为不存在'同类数据催化'锚点，强行检索试验启动类事件只会引入噪声
方向:无需先例：本条不含数据读出或阶段迁移，不属于可定价的临床事件；近 72 小时已处理的多起 UEG Week UC II/III 期数据事件（礼来 Omvoh、武田 ENTYVIO、Odyssey、Teva/赛诺菲 duvakitug）即便有阳性数据，对 mega-cap 药企均无显著正收益，本条（无数据）强度严格更低
涨幅量级:无对齐先例可用，也无需以先例校准幅度——例行注册更新对赛诺菲基本面弹性近似为零
形态:不适用
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,501 ms
{"result": "search_processed_events:agent query=`nct06867094 sar441566 ulcerative colitis trial status | sanofi sar441566 uc dose ranging study | sar441566 溃疡性结肠炎 phase 2`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、22644 条本臂决策(完整)，返回 10 条候选。\n• 10-19 09:59 UTC(北京 17:59) [bm25:52%] 不做 LLY.US (rttnews_biotec - web_search 成功 doubao_search · 1,847 ms
豆包搜索结果（原始查询:SAR441566 Sanofi drug mechanism phase 2 ulcerative colitis NCT06867094；API SearchType:web）
原文全文
展开原文 · 1,103 字
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.
This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment.
Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study).
* The study duration will be up to 59 weeks.
* The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm.
* The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment.
Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study).
* The study duration will be up to 59 weeks.
* The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm.
* The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
fa1ff084dc· 2026-10-21 20:16 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前